Literature DB >> 26590944

Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model.

Xiang Huang1, Shiyun Cui1, Yongqian Shu2.   

Abstract

The objective of this study was to investigate the immunomodulatory effect of cisplatin (DDP) on the frequency, phenotype and function of myeloid-derived suppressor cells (MDSC) in a murine B16 melanoma model. C57BL/6 mice were inoculated with B16 cells to establish the murine melanoma model and randomly received treatment with different doses of DDP. The percentages and phenotype of MDSC after DDP treatment were detected by flow cytometry. The immunoinhibitory function of MDSC was analyzed by assessing the immune responses of cocultured effector cells through CFSE-labeling assay, detection of interferon-γ production and MTT cytotoxic assay, respectively. Tumor growth and mice survival were monitored to evaluate the antitumor effect of combined DDP and adoptive cytokine-induced killer (CIK) cell therapy. DDP treatment selectively decreased the percentages, modulated the surface molecules and attenuated the immunoinhibitory effects of MDSC in murine melanoma model. The combination of DDP treatment and CIK therapy exerted synergistic antitumor effect against B16 melanoma. DDP treatment selectively downregulated the frequency and immunoinhibitory function of MDSC in B16 melanoma model, indicating the potential mechanisms mediating its immunomodulatory effect.

Entities:  

Keywords:  Chemotherapeutic drugs; Cisplatin; Immunomodulation; Myeloid-derived suppressor cells

Mesh:

Substances:

Year:  2016        PMID: 26590944     DOI: 10.1007/s12026-015-8734-1

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  40 in total

Review 1.  Myeloid-derived suppressor cells in cancer patients: a clinical perspective.

Authors:  Alberto J Montero; Claudia Marcela Diaz-Montero; Christos E Kyriakopoulos; Vincenzo Bronte; Susanna Mandruzzato
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

Review 2.  Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.

Authors:  Oana Draghiciu; Joyce Lubbers; Hans W Nijman; Toos Daemen
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

3.  All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.

Authors:  Noweeda Mirza; Mayer Fishman; Ingo Fricke; Mary Dunn; Anthony M Neuger; Timothy J Frost; Richard M Lush; Scott Antonia; Dmitry I Gabrilovich
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

4.  Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine.

Authors:  Shiwen Peng; Sofia Lyford-Pike; Belinda Akpeng; Annie Wu; Chien-Fu Hung; Drew Hannaman; John R Saunders; T-C Wu; Sara I Pai
Journal:  Cancer Immunol Immunother       Date:  2012-08-04       Impact factor: 6.968

Review 5.  The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.

Authors:  Thomas F Gajewski
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

Review 6.  Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.

Authors:  Katherine H Parker; Daniel W Beury; Suzanne Ostrand-Rosenberg
Journal:  Adv Cancer Res       Date:  2015-05-12       Impact factor: 6.242

7.  Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models.

Authors:  Maria Jure-Kunkel; Gregg Masters; Emel Girit; Gennaro Dito; Francis Lee; John T Hunt; Rachel Humphrey
Journal:  Cancer Immunol Immunother       Date:  2013-07-20       Impact factor: 6.968

8.  Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.

Authors:  Stephanie K Bunt; Ashley M Mohr; Jennifer M Bailey; Paul M Grandgenett; Michael A Hollingsworth
Journal:  Cancer Immunol Immunother       Date:  2012-08-05       Impact factor: 6.968

9.  IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.

Authors:  Susanna Mandruzzato; Samantha Solito; Erika Falisi; Samuela Francescato; Vanna Chiarion-Sileni; Simone Mocellin; Antonio Zanon; Carlo R Rossi; Donato Nitti; Vincenzo Bronte; Paola Zanovello
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

Review 10.  Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Rui-xian Han; Xu Liu; Pan Pan; Ying-jie Jia; Jian-chun Yu
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

View more
  22 in total

Review 1.  Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.

Authors:  Hua Zheng; Masha Zeltsman; Marjorie G Zauderer; Takashi Eguchi; Raj G Vaghjiani; Prasad S Adusumilli
Journal:  Immunotherapy       Date:  2017-09       Impact factor: 4.196

Review 2.  Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.

Authors:  Sayuri Miyauchi; Sangwoo S Kim; John Pang; Kathryn A Gold; J Silvio Gutkind; Joseph A Califano; Loren K Mell; Ezra E W Cohen; Andrew B Sharabi
Journal:  Clin Cancer Res       Date:  2019-02-27       Impact factor: 12.531

Review 3.  Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.

Authors:  Arielle L Heeke; Antoinette R Tan
Journal:  Cancer Metastasis Rev       Date:  2021-06-08       Impact factor: 9.237

Review 4.  Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.

Authors:  Gabor J Szebeni; Csaba Vizler; Lajos I Nagy; Klara Kitajka; Laszlo G Puskas
Journal:  Int J Mol Sci       Date:  2016-11-23       Impact factor: 5.923

5.  Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer.

Authors:  Tal Flieswasser; Jinthe Van Loenhout; Laurie Freire Boullosa; Astrid Van den Eynde; Jorrit De Waele; Jonas Van Audenaerde; Filip Lardon; Evelien Smits; Patrick Pauwels; Julie Jacobs
Journal:  Cells       Date:  2020-06-16       Impact factor: 6.600

Review 6.  Recent advances in triple negative breast cancer: the immunotherapy era.

Authors:  Antonio Marra; Giulia Viale; Giuseppe Curigliano
Journal:  BMC Med       Date:  2019-05-09       Impact factor: 8.775

7.  Astaxanthin Treatment Induces Maturation and Functional Change of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice.

Authors:  Seong Mun Jeong; Yeon-Jeong Kim
Journal:  Antioxidants (Basel)       Date:  2020-04-23

8.  Dynamic changes in immune cell profile in head and neck squamous cell carcinoma: Immunomodulatory effects of chemotherapy.

Authors:  Hideyuki Takahashi; Koichi Sakakura; Ikko Mito; Shota Ida; Kazuaki Chikamatsu
Journal:  Cancer Sci       Date:  2016-06-24       Impact factor: 6.716

Review 9.  Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.

Authors:  Emile J Clappaert; Aleksandar Murgaski; Helena Van Damme; Mate Kiss; Damya Laoui
Journal:  Front Immunol       Date:  2018-10-08       Impact factor: 7.561

10.  Oxaliplatin regulates myeloid-derived suppressor cell-mediated immunosuppression via downregulation of nuclear factor-κB signaling.

Authors:  Na-Rae Kim; Yeon-Jeong Kim
Journal:  Cancer Med       Date:  2018-12-27       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.